ENSG00000223804 and myeloproliferative neoplasm: Noteworthy, FLT3i quizartinib and JAK1/2i ruxolitinib enhanced the effect of the combinations of Polθi + ALDHi and Polθi + ADH5i in AML and MPN patient cells.